Health

Research Sheds Light on Aspirin’s Role in Reducing Cancer Risk

New studies reveal how aspirin may reduce cancer metastasis and recurrence, especially in colorectal cancer patients with specific genetic mutations.

Bluxle Editorial Updated April 21, 2026 2 min read AI-Researched
Image credit: Low-dose aspirin can prevent bowel cancer in people with Lynch syndrome - Cancer Research UK - Cancer News / Amal Iman
Image credit: Low-dose aspirin can prevent bowel cancer in people with Lynch syndrome - Cancer Research UK - Cancer News / Amal Iman
Article Bias Score Neutral
◀ Left Right ▶

Recent research has provided insights into how aspirin may help reduce the risk of cancer metastasis and recurrence. Aspirin’s ability to inhibit platelet COX‑1–dependent thromboxane A₂ (TXA₂) production plays a crucial role in disrupting platelet‑tumor cell interactions and immune suppression, thereby suppressing metastatic dissemination across multiple cancer types [1][2].

Studies have shown that aspirin enhances immunity to cancer metastasis by releasing T cells from suppression by platelet‑derived TXA₂ via the ARHGEF1‑dependent immunosuppressive pathway, reducing metastasis in preclinical models [1][2].

In patients with colorectal cancer harboring PIK3CA mutations, daily aspirin (160 mg) after treatment has been found to reduce the risk of cancer recurrence by approximately 50–55% [3][4]. Additionally, for individuals with Lynch syndrome, a hereditary condition that increases the risk of colorectal cancer, low‑dose aspirin (75–100 mg daily) has been shown to halve the risk of bowel cancer [5][6].

Image credit: Millions take aspirin to prevent colon cancer. A major review says don’t count on it | ScienceDaily
Image credit: Millions take aspirin to prevent colon cancer. A major review says don’t count on it | ScienceDaily | Credit: Millions take aspirin to prevent colon cancer. A major review says don’t count on it | ScienceDaily

Long-term use of low‑dose aspirin (75–100 mg) for five or more years has been associated with a 20–40% reduction in colorectal cancer incidence, likely due to the inhibition of the COX‑2/PGE₂ pathway [7].

What Is Known

The mechanistic insights regarding aspirin’s role in reducing cancer metastasis have been confirmed by studies published in reputable journals, including Nature and MDPI [1][2]. The reduction in recurrence risk for colorectal cancer patients with PIK3CA mutations has been supported by findings from the ALASCCA trial and reported by ASCO Post and Medical Xpress [3][4]. The effectiveness of low‑dose aspirin in reducing bowel cancer risk in Lynch syndrome patients has been confirmed by Cancer Research UK and the CaPP3 trial [5][6].

Image credit: Does Low Dose Aspirin Raise Cancer Risk? Study Offers Clues

Image credit: Does Low Dose Aspirin Raise Cancer Risk? Study Offers Clues | Credit: Does Low Dose Aspirin Raise Cancer Risk? Study Offers Clues

What Remains Unclear

While aspirin’s role in reducing colorectal cancer incidence over the long term is supported by some studies, the Cochrane review suggests that aspirin does not reliably prevent colorectal cancer in average-risk individuals within the first 5–15 years, and bleeding risks begin immediately [8]. Additionally, the claim that aspirin increases cancer-related mortality in older adults remains unconfirmed [9].

AI-Generated Content Disclosure

This article was generated by Bluxle's AI system based on research from multiple news sources. All facts are sourced and cited below. The AI is designed to be neutral and fact-based with no editorial opinion.

Editorially reviewed by R McLennan

Sources & Citations

Source Bias Score Neutral
◀ Left Right ▶

Weighted by citation frequency — sources cited more often carry greater influence.

Research Basis

Outlets in bold were actively consulted during research for this article. Others are in our standard monitoring pool.